BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
JEMPERLI (dostarlimab) by GSK is programmed death receptor-1-directed antibody interactions [moa]. Approved for endometrial cancer. First approved in 2021.
JEMPERLI (dostarlimab) is a PD-1 blocking monoclonal antibody approved in April 2021 for treating mismatch repair-deficient (dMMR) endometrial cancer. It works by enabling the immune system to recognize and attack cancer cells by blocking the programmed death receptor-1 pathway. The drug represents a significant advancement in immunotherapy for gynecologic malignancies.
$0.002BPart D
PeakProduct is at peak lifecycle with established commercial presence; teams focus on maintaining market position and expanding indications in a competitive immunotherapy space.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications (1)
Clinical Trials (20)
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
Started Jan 2026
270 enrolled
Locally Advanced Rectal Cancer (LARC)
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Started Nov 2025
30 enrolled
Neoplasms, Endometrial
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Started Oct 2025
25 enrolled
MMRd/MSI-H Stage II-III Endometrial Cancer
pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer
Started Sep 2025
40 enrolled
Endometrial Cancer
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
Started Jul 2025
100 enrolled
Neoplasms, Endometrial
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.